Details

Autor(en) / Beteiligte

• Mehra, Ranee
• Huang, Huan
• Seal, Brian
• Tse, Jenny
• Shenolikar, Rahul A.
• Burudpakdee, Chakkarin

Titel

Real‐world treatment patterns for patients with metastatic head and neck squamous cell carcinoma treated with immuno‐oncology therapy

Ist Teil von

• Head & neck, 2020-08, Vol.42 (8), p.2030-2038

Ort / Verlag

Hoboken, USA: John Wiley & Sons, Inc

Erscheinungsjahr

2020

Quelle

Wiley Online Library

Beschreibungen/Notizen

• Background Real‐world use of immuno‐oncology (IO) therapies (nivolumab and pembrolizumab) in metastatic head and neck squamous cell carcinoma (mHNSCC) has not been well studied. Methods mHNSCC patients treated with an IO therapy were identified from a large US claims database from 2016 to 2017. Treatment patterns before and after initiation of IO therapy (index date) were described. Results Among 416 mHNSCC patients, 85% had ≥1 regimen prior to IO therapy. Ninety‐seven percent of patients initiated IO as monotherapy and 3% initiated IO combined with another systemic treatment. One hundred seventeen (28%) patients had a subsequent regimen, usually chemotherapy (n = 58, 50%) or IO monotherapy (n = 27, 23%), of which 22 patients restarted the same IO therapy and 5 switched to another IO monotherapy. Conclusion The majority of mHNSCC patients initiated IO as a monotherapy. Approximately half of patients with a subsequent regimen received chemotherapy and one‐fourth received IO monotherapy.